Role of miR-133a in radiation-induced cardiac injury in mice
Yan Rui1, Song Jianbo2, Guo Min3, Cai Honghong1, Xu Xianhai1, Zhang Yarong1, Yu Yang1, Li Sijin1
1Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan 030001, China; 2Department of Radiotherapy of Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences), Taiyuan 030032, China; 3Department of Cardiology, First Hospital of Shanxi Medical University, Taiyuan 030001, China
Abstract：Objective To investigate the regulatory role of microRNA in radiation-induced heart disease (RIHD) in mice and provide a new strategy for its treatment. Methods Based on the Gene Expression Omnibus database (GSE147241), which includes normal heart tissue and irradiation heart tissue, we conducted bioinformatics research and analysis to determine the differentially-expressed genes. Then, thirty male C57/BL6 mice were randomly divided into the control group, irradiation group and miR-133a overexpression intervention group. The heart received single dose of X-ray 20Gy in the irradiation group and miR-133a overexpression intervention group, but not in the control group, and then fed for 16 weeks. Cardiac function was assessed by echocardiography. Myocardial fibrosis was detected by Masson staining. The expression levels of miR-133a, CTGF, COL-1 and COL-3 mRNA were detected by qRT-PCR. The expression levels of CTGF, COL-1 and COL-3 proteins were detected by western blot. Results miR-133a was the differentially-expressed gene between the irradiation and control groups. Overexpression of miR-133a could mitigate the decrease in cardiac function and increase in myocardial collagen content (P<0.01). Meantime, overexpression of miR-133a could down-regulate the expression levels of CTGF, COL-1, COL-3 mRNA and protein (P<0.01). Conclusions Radiation increases the synthesis of collagen and leads to myocardial fibrosis remodeling. Overexpression of miR-133a can alleviate the radiation-induced myocardial fibrosis.
Yan Rui,Song Jianbo,Guo Min et al. Role of miR-133a in radiation-induced cardiac injury in mice[J]. Chinese Journal of Radiation Oncology, 2021, 30(10): 1078-1083.
[1] Wang H, Wei J, Zheng Q, et al. Radiation-induced heart disease:a review of classification, mechanism and prevention[J]. Int J Biol Sci, 2019, 15(10):2128-2138. DOI:10.7150/ijbs.35460. [2] Recht A. Radiation-induced heart disease after breast cancer treatment:how big a problem, and how much can-and should-we try to reduce it?[J]. J Clin Oncol, 2017, 35(11):1146-1148. DOI:10.1200/JCO.2016.71.4113. [3] Friedlander AH, Sung EC, Child JS. Radiation-induced heart disease after Hodgkin′s disease and breast cancer treatment:dental implications[J]. J Am Dent Assoc, 2003, 134(12):1615-1620. DOI:10.14219/jada.archive.2003.0108. [4] Steiner I. Pathology of radiation induced heart disease[J]. Rep Pract Oncol Radiother, 2020, 25(2):178-181. DOI:10.1016/j.rpor.2019.12.015. [5] van Middendorp LB, Kuiper M, Munts C, et al. Local microRNA-133a downregulation is associated with hypertrophy in the dyssynchronous heart[J]. ESC Heart Fail, 2017, 4(3):241-251. DOI:10.1002/ehf2.12154. [6] Kura B, Babal P, Slezak J. Implication of microRNAs in the development and potential treatment of radiation-induced heart disease[J]. Can J Physiol Pharmacol, 2017, 95(10):1236-1244. DOI:10.1139/cjpp-2016-0741. [7] Donnellan E, Phelan D, McCarthy CP, et al. Radiation-induced heart disease:a practical guide to diagnosis and management[J]. Cleve Clin J Med, 2016, 83(12):914-922. DOI:10.3949/ccjm.83a.15104. [8] Madan R, Benson R, Sharma DN, et al. Radiation induced heart disease:pathogenesis, management and review literature[J]. J Egypt Natl Canc Inst, 2015, 27(4):187-193. DOI:10.1016/j.jnci.2015.07.005. [9] Taunk NK, Haffty BG, Kosti JB, et al. Radiation-induced heart disease:pathologic abnormalities and putative mechanisms[J]. Front Oncol, 2015, 5:39. DOI:10.3389/fonc.2015.00039. [10] Rai SN, Ray HE, Yuan X, et al. Statistical analysis of repeated microRNA high-throughput data with application to human heart failure:a review of methodology[J]. Open Access Med Stat, 2012, 2012(2):21-31. DOI:10.2147/OAMS. S27907. [11] Meder B, Katus HA, Rottbauer W. Right into the heart of microRNA-133a[J]. Genes Dev, 2008, 22(23):3227-3231. DOI:10.1101/gad.1753508. [12] Dakhlallah D, Zhang J, Yu L, et al. MicroRNA-133a engineered mesenchymal stem cells augment cardiac function and cell survival in the infarct heart[J]. J Cardiovasc Pharmacol, 2015, 65(3):241-251. DOI:10.1097/FJC.0000000000000183. [13] Sang HQ, Jiang ZM, Zhao QP, et al. MicroRNA-133a improves the cardiac function and fibrosis through inhibiting Akt in heart failure rats[J]. Biomed Pharmacother, 2015, 71:185-189. DOI:10.1016/j.biopha.2015.02.030. [14] Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart[J]. Genes Dev, 2008, 22(23):3242-3254. DOI:10.1101/gad.1738708. [15] Chen MM, Lam A, Abraham JA, et al. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes:a potential role in heart fibrosis[J]. J Mol Cell Cardiol, 2000, 32(10):1805-1819. DOI:10.1006/jmcc.2000.1215. [16] Behnes M, Brueckmann M, Lang S, et al. Connective tissue growth factor (CTGF/CCN2):diagnostic and prognostic value in acute heart failure[J]. Clin Res Cardiol, 2014, 103(2):107-116. DOI:10.1007/s00392-013-0626-6. [17] Chen JQ, Guo YS, Chen Q, et al. TGF-β1 and HGF regulate CTGF expression in human atrial fibroblasts and are involved in atrial remodelling in patients with rheumatic heart disease[J]. J Cell Mol Med, 2019, 23(4):3032-3039. DOI:10.1111/jcmm.14165. [18] Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 regulate connective tissue growth factor:implications for a role of microRNAs in myocardial matrix remodeling[J]. Circ Res, 2009, 104(2):170-178, 6p following 178. DOI:10.1161/CIRCRESAHA.108.182535.
2021, Vol. 30 
